Phosphoinositide 3-kinase in Health and Disease
223,63 €
inkl. 7% MwSt. und
ggf. zzgl. Versand
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here we give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
- Seitenzahl: 310
- Format: PDF
- DRM: social-drm (ohne Kopierschutz)
- Erscheinungsdatum: 17.10.2010
- Herausgeber: SPRINGER